The global seasonal affective disorder market is predicted to rise due to an increase in the number of cases of seasonal affective disorder.
Over the forecast period, rising incidences of seasonal affective disorder are expected to drive market expansion. According to a survey issued by the Royal College of Psychiatrists in April 2015, around 3 out of 100 people in the United Kingdom suffer from substantial winter depression.
However, the market is projected to be hampered by the negative effects of seasonal affective disorder medications such as Bupropion. According to an article released by the National Center for Biotechnology Information (NCBI) in October 2020, the medicine Bupropion, which has been approved by the US Food and Drug Administration, has a number of side effects, including ophthalmologic issues such as blurred vision.
Read more @ https://cmilatestinsights.blogspot.com/2022/02/seasonal-affective-disorder-market.html
